EOFlow has announced that the company will conduct two clinical studies in 2021, both supported by Korean government research grants.
One study will be aiming at Type 2 diabetic people using the current wearable disposable insulin pump, EOPatch. This study involves four university-hospitals and up to 120 Type 2 diabetic patients.
The other study will be aiming at Type 1 diabetic people using EOFlow's first wearable closed-loop solution (automated insulin delivery), EOPatch X. This study has 6 university-hospitals signed up and aims to conduct studies on up to 108 patients. EOFlow has licensed TypeZero closed-loop algorithm which was adopted by at least one major durable pump company in the US and cleared the FDA for commercialization.